Section of Cardiology, Department of Pediatrics, The Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan.
Section of Cardiology, Department of Pediatrics, The Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, Michigan.
JACC Clin Electrophysiol. 2017 Aug;3(8):830-841. doi: 10.1016/j.jacep.2017.01.015. Epub 2017 Apr 26.
The purpose of this study was to use direct cardiac resynchronization therapy (CRT)-paced contractility (dP/dt-max) response as a pre-implantation evaluation among patients with congenital heart disease (CHD) and follow clinical parameters and contractility indexes after CRT implantation.
Patients with CHD often develop early heart failure with few therapeutic options, leading to heart transplantation (HT). Unfortunately, guidelines for CRT do not apply, and function evaluations by cardiac ultrasound are often inaccurate among CHD anatomies. Therefore, which CHD patients would benefit from CRT remains an enigma.
From 1999 to 2015, 103 CHD patients with New York Heart Association (NYHA) functional class II to IV were listed for HT; 40 patients on optimal medical therapy were referred for paced contractility response cardiac catheterization before CRT consideration. If dP/dt-max improved ≥15% from baseline, these "responders" were given the option of CRT with continued follow-up after implantation.
Of 40 patients studied, 26 (65%) (age 22 ± 8.2 years; 9 of 26 [35%] single or systemic right ventricle; 17 of 26 [65%] with pacemakers) met criteria for possible hemodynamic benefit and underwent CRT implantation. All 26 patients improved in NYHA functional classification: 5 of 26 patients (19%) were later relisted for HT (4 to 144 months, mean 55 months) after CRT implantation, whereas 21 of 26 (81%) continued with improved NYHA functional class (12 to 112 months, mean 44 months) later. A repeat dP/dt-max study following long-term CRT showed stable function or continued contractility improvement.
Heart failure is common among CHD patients, and therapies are limited. CRT guidelines do not address clinical and anatomic issues of CHD. Short-term paced contractility response testing identifies those CHD patients who are likely to respond to CRT regardless of anatomy.
本研究旨在通过直接心脏再同步治疗(CRT)起搏收缩力(dP/dt-max)反应作为先天性心脏病(CHD)患者的植入前评估,并在 CRT 植入后随访临床参数和收缩力指标。
CHD 患者常因早期心力衰竭而出现,治疗选择有限,导致心脏移植(HT)。不幸的是,CRT 指南并不适用,CHD 解剖结构中心脏超声功能评估往往不准确。因此,哪些 CHD 患者受益于 CRT 仍然是个谜。
1999 年至 2015 年,103 例 NYHA 心功能 II 至 IV 级的 CHD 患者被列入 HT 名单;40 例接受最佳药物治疗的患者在考虑 CRT 前接受起搏收缩力反应心导管检查。如果 dP/dt-max 从基线改善≥15%,则这些“反应者”可选择接受 CRT,并在植入后继续随访。
在 40 例研究患者中,26 例(65%)(年龄 22±8.2 岁;26 例中有 9 例[35%]为单一或全身右心室;26 例中有 17 例[65%]有起搏器)符合可能有血流动力学获益的标准,并接受 CRT 植入。26 例患者的 NYHA 心功能分级均有改善:26 例患者中有 5 例(19%)在 CRT 植入后(4 至 144 个月,平均 55 个月)再次被列入 HT 名单,而 21 例(81%)继续保持改善的 NYHA 心功能分级(12 至 112 个月,平均 44 个月)。长期 CRT 后重复 dP/dt-max 研究显示功能稳定或持续收缩力改善。
心力衰竭在 CHD 患者中很常见,治疗方法有限。CRT 指南并未解决 CHD 的临床和解剖问题。短期起搏收缩力反应测试可识别出无论解剖结构如何,可能对 CRT 有反应的 CHD 患者。